Perspective Therapeutics (CATX) Operating Expenses (2010 - 2026)

Perspective Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $28.4 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 27.88% year-over-year to $28.4 million; the TTM figure through Mar 2026 stood at $120.6 million (up 19.22% YoY), while the FY2025 annual figure was $114.4 million, up 23.94% from the prior year.
• Operating Expenses came in at $28.4 million for Q1 2026 at Perspective Therapeutics, down from $39.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $45.2 million in Q4 2024 to a low of $2.8 million in Q1 2022.
• A 5-year average of $17.3 million and a median of $13.3 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 276.41% in 2024 and slipped 11.82% in 2025, its largest moves.
• Perspective Therapeutics' Operating Expenses stood at $5.6 million in 2022, then soared by 113.72% to $12.0 million in 2023, then soared by 276.41% to $45.2 million in 2024, then retreated by 11.82% to $39.9 million in 2025, then dropped by 28.89% to $28.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $28.4 million, $39.9 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison